title: Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF.
abstract: OBJECTIVE
  To determine whether pretreatment of retinal pigmented epithelial (RPE) cells with lutein can affect the response of cells to bevacizumab therapy.
  
  
  METHODS
  One human RPE cell line (ARPE-19) was used for all experiments. The cells were treated with lutein in different concentrations (0.01, 0.1, 1, 10, or 100 μg/ml). After 24 h, all plates were treated with bevacizumab (0.25 mg/ml). Media were harvested 24 h later for sandwich ELISA-based angiogenesis arrays. A Quantibody Human Angiogenesis Array was used in order to quantify the secretion of the following 10 proangiogenic cytokines: angiogenin, ANG2, EGF, bFGF, HB-EGF, PDGF-BB, leptin, PIGF, HGF and VEGF.
  
  
  RESULTS
  Treatment with bevacizumab alone led to a significant decrease in VEGF, as well as a significant increase in angiogenin and bFGF. Pretreatment with 0.1 and 1.0 μg/ml of lutein led to significant decreases in both bFGF and angiogenin following treatment with bevacizumab compared to bevacizumab treatment alone. Lutein alone did not modify the secretion of proangiogenic cytokines.
  
  
  CONCLUSIONS
  Pretreatment of human RPE cells in culture with specific doses of lutein prior to bevacizumab treatment mitigated the increase in bFGF and angiogenin caused by bevacizumab monotherapy.
authors.affiliation: Henry C. Witelson Ocular Pathology Laboratory, Montreal, Que., Canada.
authors.forename: Natàlia
authors.initials: N
authors.lastname: Vilà
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Coblentz
authors.forename: Carlos
authors.initials: C
authors.lastname: Moreira-Neto
authors.forename: Vasco
authors.initials: V
authors.lastname: Bravo-Filho
authors.forename: Pablo
authors.initials: P
authors.lastname: Zoroquiain
authors.forename: Miguel N
authors.initials: MN
authors.lastname: Burnier
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000068258:Bevacizumab / Q000494:pharmacology*; D002470:Cell Survival; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D014975:Lutein / Q000494:pharmacology*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D012259:Ribonuclease, Pancreatic / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; C046366:angiogenin; D012259:Ribonuclease, Pancreatic; D014975:Lutein